South Korea
· Delayed Price · Currency is KRW Cytogen Statistics
Total Valuation
Cytogen has a market cap or net worth of KRW 177.17 billion. The enterprise value is 138.63 billion.
| Market Cap | 177.17B |
| Enterprise Value | 138.63B |
Important Dates
The next estimated earnings date is Friday, November 29, 2024.
| Earnings Date | Nov 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Cytogen has 23.07 million shares outstanding. The number of shares has increased by 15.25% in one year.
| Shares Outstanding | 23.07M |
| Shares Change (YoY) | +15.25% |
| Shares Change (QoQ) | +0.45% |
| Owned by Insiders (%) | 21.26% |
| Owned by Institutions (%) | 0.03% |
| Float | 11.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 44.33 |
| PB Ratio | 3.15 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.73 |
| EV / Sales | 39.01 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -15.04 |
Financial Position
The company has a current ratio of 17.28, with a Debt / Equity ratio of 0.25.
| Current Ratio | 17.28 |
| Quick Ratio | 16.73 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.48 |
| Interest Coverage | -6.27 |
Financial Efficiency
Return on equity (ROE) is -51.04% and return on invested capital (ROIC) is -16.48%.
| Return on Equity (ROE) | -51.04% |
| Return on Assets (ROA) | -14.43% |
| Return on Capital (ROIC) | -16.48% |
| Revenue Per Employee | 63.46M |
| Profits Per Employee | -283.44M |
| Employee Count | 56 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 19.65 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -52.45% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -52.45% |
| 50-Day Moving Average | 7,507.60 |
| 200-Day Moving Average | 10,810.35 |
| Relative Strength Index (RSI) | 59.99 |
| Average Volume (20 Days) | 19,072 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cytogen had revenue of KRW 3.55 billion and -15.87 billion in losses. Loss per share was -773.78.
| Revenue | 3.55B |
| Gross Profit | 555.22M |
| Operating Income | -12.57B |
| Pretax Income | -16.35B |
| Net Income | -15.87B |
| EBITDA | -10.76B |
| EBIT | -12.57B |
| Loss Per Share | -773.78 |
Balance Sheet
The company has 52.19 billion in cash and 13.65 billion in debt, giving a net cash position of 38.54 billion or 1,670.73 per share.
| Cash & Cash Equivalents | 52.19B |
| Total Debt | 13.65B |
| Net Cash | 38.54B |
| Net Cash Per Share | 1,670.73 |
| Equity (Book Value) | 54.57B |
| Book Value Per Share | 2,440.02 |
| Working Capital | 52.52B |
Cash Flow
In the last 12 months, operating cash flow was -8.58 billion and capital expenditures -638.72 million, giving a free cash flow of -9.22 billion.
| Operating Cash Flow | -8.58B |
| Capital Expenditures | -638.72M |
| Free Cash Flow | -9.22B |
| FCF Per Share | -399.57 |
Margins
| Gross Margin | 15.62% |
| Operating Margin | -353.80% |
| Pretax Margin | -460.13% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -259.39% |
Dividends & Yields
Cytogen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.25% |
| Shareholder Yield | -15.25% |
| Earnings Yield | -10.08% |
| FCF Yield | -5.20% |
Stock Splits
The last stock split was on September 28, 2022. It was a forward split with a ratio of 3.
| Last Split Date | Sep 28, 2022 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
Cytogen has an Altman Z-Score of 6.83.
| Altman Z-Score | 6.83 |
| Piotroski F-Score | n/a |